clinical research 
Clindamycin hydrochloride mainly has strong antibacterial ability against Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus hemolyticus, Streptococcus viridis, and many anaerobic bacteria. Most Gram negative bacteria are resistant to clindamycin. However, some special strains, such as Corynebacterium diphtheriae and Clostridium tetanus, are sensitive to clindamycin hydrochloride.
Therefore, clinically used for drug-resistant tonsillitis, suppurative otitis media, osteomyelitis, respiratory system infections (bronchiectasis infection, lung abscess, acute attack of chronic bronchitis), sepsis, female reproductive tract, pelvic and abdominal infections, and soft tissue infections (furuncle, carbuncle, abscess, post traumatic infection) caused by Staphylococcus aureus, anaerobic bacteria, and streptococcus.
Infections caused by anaerobic bacteria include: empyema, lung abscess, anaerobic pneumonia, skin and soft tissue infection, sepsis, peritonitis, abdominal abscess, endometritis, ovarian abscess, pelvic cellulitis, and infections after gynecological surgery.
Another unique clinical value of clindamycin is that it is an optional medication for gram-positive bacteria in many patients with cephalosporin and penicillin allergies. Patients with penicillin allergy, such as appendicitis, infective endocarditis, and hemolytic streptococcal infection, should choose clindamycin as an alternative drug. Clindamycin is metabolized through the liver, so it is necessary to consider the patient's liver function, without considering changes in renal function (when renal function decreases, the original dose can be used).
matters needing attention
The pharmacokinetics of clindamycin is similar to that of penicillin and cephalosporins, and it is a time-dependent antibacterial drug. Therefore, multiple doses per day can ensure the maximum efficacy of the drug in the body. Concentration dependent antibiotics such as aminoglycosides and fluoroquinolones can be administered once a day. The general course of treatment for antibacterial drugs is usually 96 hours after use until the body temperature is normal and symptoms are relieved. Patients with localized lesions need complete control of the infected lesion.
Therefore, patients often try to save time and change the frequency of medication without authorization, using large doses at once, which makes it difficult to achieve the ideal bactericidal concentration of the drug.
Previous analysis of antibacterial drug prescriptions in emergency and outpatient departments showed that clindamycin hydrochloride palmitate dispersible tablets often have a low frequency of administration, resulting in poor treatment efficacy.